Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Alnylam to File Its Third Drug in Japan 3 Years after Market Entry, Eyes CNS Therapies
Three years after its foray into the Japanese market, RNA interference (RNAi) pioneer Alnylam Pharmaceuticals says it is poised to file its third drug in the country before the end of 2021. Beyond this product, vutrisiran, the company is looking…
To read the full story
Related Article
- Alnylam Japan Paints Two-Digit Annual Growth Outlook on ATTR Meds and Pipeline Drugs
September 14, 2022
- Alnylam Seeks Japan Approval for Vutrisiran for FAP
December 21, 2021
- Alnylam Plants Flag in Japan Soil, Eyes 4 RNAi Therapeutic Launches in 5 Years
September 28, 2018
BUSINESS
- SSP Looks to Broaden Switch OTC Portfolio under New President
April 13, 2026
- Otsuka Targets Around 2030 US Launch for Transcend’s PTSD Candidate
April 13, 2026
- Nippon Shinyaku, xFOREST Ink RNA-Targeting Small Molecule Research Pact
April 13, 2026
- OTC-Like Drug Reform Seen Adding 190 Billion Yen to Japan OTC Market by 2040: Fuji Keizai
April 13, 2026
- AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
April 13, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…